News | Peripheral Artery Disease (PAD) | May 05, 2016

Positive Twelve-Month TOBA-BTK Results Presented at SCAI 2016

Data demonstrate sustained vessel patency and low re-intervention rates with the Tack Endovascular System in critical limb ischemia patients

TOBA-BTK study, twelve-month results, SCAI 2016, Tack Endovascular System, critical limb ischemia

May 5, 2016 — Intact Vascular Inc. announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty – Below-the-Knee (TOBA-BTK) clinical study were presented at the SCAI 2016 conference. Results were presented by Dr. Christian Wissgott, assistant director at Westküstenklinikum Heide in Heide, Germany.

The TOBA-BTK study enrolled 35 subjects at six sites in Europe and New Zealand. All study subjects were suffering from critical limb ischemia, a form of peripheral arterial disease, in one or both legs. Of the subjects enrolled, 32 were treated with the 4 French Tack Endovascular System following standard balloon angioplasty in the tibial and peroneal arteries. The Tack Endovascular System is a new technology designed to repair dissections (or tears) in the artery wall that frequently occur as a complication of balloon angioplasty. The system allows physicians to repair these dissections while leaving a minimal amount of foreign material in the artery, reducing mechanical stress on the artery, and preserving future treatment options.

Some of the key conclusions from the TOBA-BTK study included:

  • 78.4 percent 12-month primary patency;
  • 89.2 percent 12-month primary assisted patency;
  • 93.5 percent freedom from target lesion revascularization (TLR);
  • 84.5 percent amputation-free survival; and
  • 87.1 percent freedom from major amputation.

Wissgott stated, “Restoring blood flow to the legs in patients with critical limb ischemia is vitally important to their quality of life and survival. We have few treatments that have a demonstrated ability to keep the small arteries below the knee open over 12 months, so these TOBA-BTK results are truly encouraging. These data suggest that repairing arterial dissections following angioplasty below the knee, using the minimal metal design approach of the Tack implant, can keep the treated arteries open and blood flowing.”

Patients in the study demonstrated a marked improvement as measured by the Rutherford Classification System, a seven-stage scale ranging from no symptoms (class 0) to gangrene (class 6). The study data suggest that an increasing number of patients continue to improve, with 75 percent of patients experiencing a four- or five-step improvement in Rutherford Classification from baseline (p<0.0001) at 12 months.

Wissgott continued, “The Tack Endovascular System holds much promise for improving the long-term outcomes associated with balloon angioplasty below the knee. I look forward to building on these exciting results in the expanded TOBA II BTK clinical trial that is currently being planned.”

Based on these results, the company is pursuing an expanded study (TOBA II BTK) that will assess the performance of the Tack Endovascular System in a larger population and will include U.S. and international investigators.

For more information: www.intactvascular.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init